Critical Comparison: Galmed Pharmaceuticals (GLMD) & Its Competitors

Galmed Pharmaceuticals (NASDAQ: GLMD) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Galmed Pharmaceuticals to related businesses based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.

Earnings and Valuation

This table compares Galmed Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Galmed Pharmaceuticals $470,000.00 -$16.95 million -7.25
Galmed Pharmaceuticals Competitors $284.49 million $34.10 million 70.46

Galmed Pharmaceuticals’ competitors have higher revenue and earnings than Galmed Pharmaceuticals. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Galmed Pharmaceuticals has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals’ competitors have a beta of 2.68, meaning that their average stock price is 168% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Galmed Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals 0 0 4 0 3.00
Galmed Pharmaceuticals Competitors 882 3259 11753 235 2.70

Galmed Pharmaceuticals currently has a consensus target price of $20.75, indicating a potential upside of 134.73%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.44%. Given Galmed Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Galmed Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Galmed Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galmed Pharmaceuticals -1,242.49% -167.83% -110.52%
Galmed Pharmaceuticals Competitors -5,346.43% -217.96% -40.67%

Institutional & Insider Ownership

9.9% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Galmed Pharmaceuticals competitors beat Galmed Pharmaceuticals on 8 of the 13 factors compared.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company’s Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

What are top analysts saying about Galmed Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Galmed Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit